OR WAIT null SECS
December 09, 2024
The first CPHI Middle East event will be held Dec. 10–12, 2024 at the Riyadh Front Exhibition & Convention Center Riyadh in Saudi Arabia and is expected to be host to 30,000 pharma professionals.
Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies.
December 06, 2024
The draft guidance provides information on the agency’s accelerated approval process and criteria for approval.
Lilly is investing $3 billion to expand its recently acquired manufacturing facility in Wisconsin, while Amgen is investing $1 billion to expand its facility in North Carolina.
Through the agreement, Cambrex will provide accelerated access to clinical development capabilities to Lilly’s biotech collaborators.
December 04, 2024
The agency’s safety committee found no sufficient evidence of causal relationship between the antibiotic doxycycline and the risk of suicide or suicidal thoughts.
The European Commission has developed a roadmap aimed at reversing the rising trend of cancer across the European Union.
EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
With its new offering, Lonza can tailor services to support smart capsule companies with its bi-layer capsule manufacturing technology.
December 03, 2024
Edwin Stone, Bernard Sagaert, and Khaled Yamout go behind the headlines to discuss what the ongoing measles outbreak in the UK means for pandemic preparedness and anti-vaccination trends; new mRNA approaches; and what Roche’s acquisition of Poseida means for complex cell therapies.